SCHEMBL17629985

SCHEMBL17629985

CCc1cc([N+](=O)[O-])cnc1-c1ccc(C#N)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
NPC1 O15118 2/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.41
VCAM1 P19320 1/20 0.41
GLA P06280 2/20 0.39
GAA P10253 2/20 0.39
HTT P42858 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
KDM1A O60341 1/20 0.38
KCNJ1 P48048 1/20 0.38
KCNH2 Q12809 1/20 0.38
PTPN11 Q06124 1/20 0.37
CYP11B2 P19099 1/20 0.37
FLT1 P17948 1/20 0.36
FLT4 P35916 1/20 0.36
KDR P35968 1/20 0.36
HSD11B1 P28845 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17629945 0.81 VCAM1 (0.47) MAPTNPC1PKMVCAM1GAA
SCHEMBL17630181 0.81 VCAM1 (0.42) MAPTNPC1PKMVCAM1GLA
SCHEMBL17629905 0.79 GAA (0.41) MAPTNPC1PKMVCAM1GLA
SCHEMBL17630044 0.78 KDM1A (0.41) MAPTKDM1AKCNH2PTPN11CYP11B2
SCHEMBL17629867 0.78 PTPN11 (0.43) KDM1APTPN11CYP11B2CYP2A6
SCHEMBL17629991 0.78 GAA (0.41) MAPTNPC1PKMRAB9AVCAM1
SCHEMBL17630051 0.77 GAA (0.46) MAPTNPC1PKMVCAM1GLA
SCHEMBL4725911 0.76 VCAM1 (0.42) MAPTNPC1PKMVCAM1GLA
SCHEMBL18449675 0.73 MAPT (0.52) MAPTNPC1PKMRAB9AVCAM1
SCHEMBL14988218 0.72 MAPT (0.48) MAPTNPC1PKMRAB9AVCAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016046782-A1 IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2016-03-31 WO disclosed